-
Your Citizen Science At Work
By sharing your anonymous data through The Duchenne Registry, you are strengthening the power of […]
-
Phase 1/2 update ‘encouraging’ for DMD gene therapy RGX-202
The experimental gene therapy RGX-202 has been found to be well tolerated at a high […]
-
I’m at a crossroads in life, once again
Starting last week, I’ve been trying to get my life back on track after enduring […]
-
PGN-ED051, skipping exon 51, showing benefits in Phase 2 trial
A low dose of PGN-ED051, PepGen’s investigational exon 51-skipping therapy, safely increased dystrophin protein levels […]
-
Clinical Trials & Outcome Measures in Duchenne
Clinical trials and research studies are vitally important to improving health and quality of life […]
-
Ladies Luncheon Returns to Austin Country Club on September 26 for an “Afternoon in NYC” Benefiting CureDuchenne
Annual Event Features an Afternoon of Fashion and Fun to Raise Funds to Help Find […]
-
cTAP Study Indicates Duchenne Muscular Dystrophy Clinical Trial Enrollment Criteria Should Expand Beyond Ambulatory Status
Study Co-Funded by CureDuchenne and cTAP Highlights Need for More Specific Enrollment Criteria That Could […]
-
In ‘Muscle Memoirs,’ I’ll share tales of life with LGMD
Muscular dystrophy entered my life in the fall of 1984. I was 11 years old […]
-
Finding beauty in how Duchenne has shaped our lives
Duchenne muscular dystrophy (DMD) touches every part of my family’s life. Jason, my husband of […]
-
REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
Link to press release We are thrilled to share the latest data from RegenXBio’s microdystrophin […]
